A phase I trial of gemcitabine administered as a 96-h continuous intravenous infusion in patients with advanced carcinoma and lymphoma

Medical Oncology

Volumn 23, Issue 3, 2006, Pages 369-376

  Rajdev, Lakshmi ^a   Goldberg, Gary ^a   Hopkins, Una ^a   Sparano, Joseph A ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

96 h; Gemcitabine; Infusional; Phase I

Indexed keywords

GEMCITABINE;

ACUTE RESPIRATORY FAILURE; ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER PATIENT; CARCINOMA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DYSPNEA; FATIGUE; FEASIBILITY STUDY; FEMALE; GYNECOLOGIC CANCER; HUMAN; HYPOTENSION; LUNG CARCINOMA; LYMPHOMA; MALE; MUCOSA INFLAMMATION; MULTIPLE DRUG DOSE; NAUSEA; NEUTROPENIA; NEUTROPHILIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; THROMBOCYTE ANOMALY; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARCINOMA; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 33749379982     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:3:369     Document Type: Article

References (21)

1. Burris HA, 3rd, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
2. Schiller JH, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
3. Yardley DA. Gemcitabine plus paclitaxel in breast cancer. Semin Oncol 2005;32:S14-21.
4. Plunkett W, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22:23-10.
5. Huang P, et al. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51:6110-6117.
6. US Food and Drug Administration website (accessed 12/24/05). http://www.accessdata.fda.gov/scripts/cder/onctools/labels.cfm?GN=gemcitabine.
7. Abbruzzese JL, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9:491-498.
8. Grunewald R, et al. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991;27:258-262.
9. Tempero M, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003;21:3402-3408.
10. Veerman G, et al. Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 1996;38:335-342.
11. Sparano JA, et al. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma. J Clin Oncol 1996;14:3026-35.
12. Sparano JA, et al. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 1993;11:1071-1079.
13. Simon R, et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-1147.
14. O'Rourke TJ, et al. Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur J Cancer 1994;30A:417-418.
15. Oken MM, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
16. Gupta N, et al. Gemcitabine-induced pulmonary toxicity: case report and review of the literature. Am J Clin Oncol 2002;25:96-100.
17. Boven E, et al. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer 1993;68:52-56.
18. Grunewald R, et al. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 1992;10:406-413.
19. Akrivakis K, et al. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anticancer Drugs 1999;10:525-531.
20. Schmid P, et al. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 1999;10:625-631.
21. Anderson H, et al. A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer 1996;74:460-462.